OnKure Therapeutics Q2 EPS $(1.14) Beats $(1.26) Estimate

OnKure Therapeutics (NASDAQ: OKUR) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.26) by 9.88 percent. This is a 97.46 percent increase over losses of $(44.82) per share from the same period last year.